In a newly published article in Nature Genetics, researchers from the University of Chicago have identified tumor aneuploidy—an imbalance in the number of chromosomes—as a powerful biomarker associated with resistance to immunotherapy across cancer types. The study emphasizes how combining immunotherapy with radiation may help overcome the issue of therapy resistance, offering a new framework for predicting treatment response and personalizing cancer therapy.